ASTEX THERAPEUTICS LIMITED

• ⚠

  Confirmation statement overdue

  Due 2026-05-16.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +45.9%

  £276,803,907 → £403,792,528

  highest in 6 filed years

• Cash

  -53.3%

  £113,799,796 → £53,101,198

• Net assets

  -18.3%

  £200,259,318 → £163,640,229

• Employees

  +5.8%

  173 → 183

  highest in 6 filed years

• Operating profit

  +56%

  £217,672,176 → £339,607,762

  highest in 6 filed years

• Profit before tax

  +51.3%

  £219,057,011 → £331,372,037

  highest in 6 filed years

• Wages

  +17.5%

  £17,976,742 → £21,130,126

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. ASTEX THERAPEUTICS LIMITED 2005-06-27 → present
2. ASTEX TECHNOLOGY LIMITED 1999-05-14 → 2005-06-27
3. INTERCEDE 1426 LIMITED 1999-04-14 → 1999-05-14

Accounting basis

IFRS

Reporting scope

Standalone (parent only)

Auditor

KPMG LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The directors have prepared the financial statements on the going concern basis as they do not intend to liquidate the Company or to cease its operations, and as they have concluded that the Company's financial position means that this is realistic. They have also concluded that there are no material uncertainties that could have cast significant doubt over its ability to continue as a going concern for at least a year from the date of approval of the financial statements ("the going concern period").”

Significant events

• “Company turnover, which includes the Research and Development Credit, has increased by 45%. This is primarily due to increased royalty payments in respect of the research collaboration with Novartis, Janssen and Astra Zeneca.”
• “There was income from Merck, Sharp and Dohme (MSD) from the collaboration signed in July 2023. There were no milestones received in the year”
• “On 10 March 2025, Astex entered into a collaboration agreement with Mosaic Therapeutics Limited (Mosaic), a venture capital backed UK company. Mosaic received licences to two clinical-stage oncology”
• “On 30 September 2025 Dr Harren Jhoti stepped down from his position as President & CEO and as a director of the Company.”
• “He was replaced by Dr Michelle Jones as Director and President on 01 October 2025.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

6

last 12 months

Capital events

0

last 24 months

Officers appointed

2

last 12 months

Officers resigned

2

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.